Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mesoblast Ltd (NASDAQ:MESO)

5.07
Delayed Data
As of 12:20pm ET
 +0.09 / +1.81%
Today’s Change
3.50
Today|||52-Week Range
13.00
-20.28%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$379.8M

Company Description

Mesoblast Ltd. develops innovative cell based medicines. The company has leveraged its proprietary technology platform, which is based on mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Contact Information

Mesoblast Ltd.
Level 38
Melbourne Victoria (vic) 3000
P:(139) 639-6036
Investor Relations:

Employees

Shareholders

Mutual fund holders2.63%
Other institutional0.78%
Individual stakeholders--

Top Executives

Silviu ItescuChief Executive Officer, Executive Director & MD
Paul HodgkinsonChief Financial Officer
Donna L. SkerrettChief Medical Officer
Jonathan Richard SymondsHead-Corporate Finance & Strategy
Michael SchusterGlobal Head-Investor Relations